1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allakos Inc.
  6. News
  7. Summary
    ALLK   US01671P1003

ALLAKOS INC.

(ALLK)
  Report
Delayed Nasdaq  -  04:00 2022-08-17 pm EDT
3.460 USD   -4.16%
08/05ALLAKOS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
08/04ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
08/04Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Allakos Files for Potential Offering of Up to $250 Million of Common Shares

05/09/2022 | 03:23am EDT


© MT Newswires 2022
All news about ALLAKOS INC.
08/05ALLAKOS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibi..
AQ
08/04ALLAKOS INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
08/04Allakos Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June ..
CI
08/04ALLAKOS : Provides Business Update and Reports Second Quarter 2022 Financial Results - For..
PU
08/04Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
GL
08/04Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
AQ
07/25ALLAKOS : Announces the Appointment of Dr. Amy Ladd to its Board of Directors - Form 8-K
PU
07/25ALLAKOS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibit..
AQ
07/25Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
GL
07/25Allakos Inc. Announces the Appointment of Dr. Amy Ladd to Its Board of Directors
CI
More news
Analyst Recommendations on ALLAKOS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -329 M - -
Net cash 2022 113 M - -
P/E ratio 2022 -0,60x
Yield 2022 -
Capitalization 198 M 198 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 192
Free-Float 93,3%
Chart ALLAKOS INC.
Duration : Period :
Allakos Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLAKOS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 3,61 $
Average target price 7,11 $
Spread / Average Target 97,0%
EPS Revisions
Managers and Directors
Robert Alexander Chief Executive Officer & Director
Adam L. Tomasi President & Chief Operating Officer
Harlan Baird Radford Chief Financial Officer
Daniel S. Janney Chairman
Ruby Casareno Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALLAKOS INC.-63.13%198
GILEAD SCIENCES, INC.-8.65%83 136
VERTEX PHARMACEUTICALS37.98%77 707
REGENERON PHARMACEUTICALS, INC.2.72%69 351
WUXI APPTEC CO., LTD.-22.47%38 993
BIONTECH SE-37.79%38 973